中国神经再生研究(英文版) ›› 2020, Vol. 15 ›› Issue (1): 63-64.doi: 10.4103/1673-5374.264456

• 观点:脑损伤修复保护与再生 • 上一篇    下一篇

脑血管病的骨膜素

  

  • 出版日期:2020-01-15 发布日期:2020-05-15

Periostin in cerebrovascular disease

Fumihiro Kawakita, Hidenori Suzuki   

  1. Department of Neurosurgery, Mie University Graduate School of Medicine, Tsu, Japan
  • Online:2020-01-15 Published:2020-05-15
  • Contact: Hidenori Suzuki, MD, PhD,suzuki02@clin.medic.mie-u.ac.jp.
  • Supported by:
    This work was funded by a grant-in-aid for Scientific Research from Japan Society for the Promotion of Science, No. 17K10825 (to HS).

摘要: orcid: 0000-0002-8555-5448 (Hidenori Suzuki)

Abstract: Cerebrovascular diseases, which include ischemic and hemorrhagic strokes, remain serious conditions with high mortality and disability worldwide (He et al., 2018). Ischemic stroke accounts for around 80% of all strokes (He et al., 2018). Hemorrhagic stroke consisting of intracerebral hemorrhage and subarachnoid hemorrhage (SAH) occurs less frequently but may cause poorer outcomes than ischemic stroke (Ji et al., 2017; Luo et al., 2018). It is also well known that aneurysmal SAH may have delayed cerebral ischemia (DCI): thus aneurysmal SAH has both characteristics of hemorrhagic and ischemic strokes (Kanamaru et al., 2019). In spite of enormous efforts to improve outcomes, no conclusive treatment exists thus far, once stroke is completed.